学术报告----WHO关于诱导广谱和持久免疫的流感疫苗的开发第四次会议

cao1976

原帖由论坛会员Rojjer发表于 2010-10-19 17:35

今日查找资料，看到了2009年11月9～10日WHO召开的"诱导广谱和持久免疫的流感疫苗的开发"第四次会议的全部报告，看了一下内容，觉得基本上包括了当前流感通用疫苗研发的全部内容，尤其是临床研究方面。特贴出来与大家一起分享.

http://www.who.int/vaccine_resea ... ov09/en/index1.html

-Update on development of H1N1 pandemic vaccines - M-P. Kieny

-Changing antigenicity of HA and NA: opportunities for improved vaccines - D. Smith

-Role of adjuvants in induction of cross-reactive and long-lasting immune responses - M. Friede

- Conserved and alternative vaccine targets - R. Bright

- Immunological correlates of protection - G. Rimmelzwaan

- Role of CMI in protection against influenza in humans - J. McElhaney

- T cell responses in human influenza virus infection - A. McMichael

- Correlates of efficacy of LAIV - K. Subbarao

- M2 cytoplasmic tail mutants as pandemic vaccine candidates - P. Bilsel

- Influenza B NS-1 truncated mutants as candidate vaccines - J. Romanova

- Protease activation mutants of influenza A and B viruses as candidates for attenuated live vaccines against pandemic and seasonal influenza - J. Stech

- Direct and indirect protection against new variants of influenza A and B with the live attenuated influenza vaccine, 2007-2008 - W.-P. Glezen

- Protection against circulating and drifted variants of influenza virus with the LAIV - I. Kiseleva

- AS03-adjuvanted seasonal vaccines in the elderly - D. Poelaert

- Enhancing the breadth of immunity to influenza VLPs - D. Compans

- Continuous production and purification of a Virus-Like Particle Influenza vaccine from mammalian cell culture - B. Dropulic

-VLPs made in insect cells and presentation of new clinical data - K. Bryett

- Insect cell-produced influenza-pseudotyped virus like particles: Evidence for enhanced immunity and breadth of protection - J. Haynes

- Overview on safety of live-vectored vaccines - R. Le Blanc

- Live-vector approaches including their MVA vector studies - L. Perera

- MVA vector studies in monkeys - A. Osterhaus

Rationale and Design of a Phase 1 Clinical Trial of PaxVax Live, Oral Ad4-Vectored H5N1 Vaccine - K. Kelley

- Non-replicating adenovirus vector as a carrier for the development of rapid-response influenza vaccines - D. Tang

- VLP production in plants - L. Vezina

- Vaccines derived from transient gene expression in tobacco plants - V. Yusibov

- A fungal platform for vaccine production - D. Higgins

- A novel universal influenza vaccine containing M2e and NP with a TLR9 agonist - T. Martin

- Flagellin fused M2e vaccines - A. Shaw - Combined vaccination with split vaccine plus M2e protein - F. Wu

- DNA Vaccines: setback, advances and next steps - J. Beadle

- Improvement of flu vaccine with adjuvants and patch delivery - A. von Gabain

- Nanoemulsion adjuvanted nasal vaccine, a novel means to enhance immunogenicity and broaden cross-protection against influenza - T. Hamouda